📡In this edition of Longevity Marketcap Telemetry

1. Last Week in Longevity

2. Longevity Futures

3. Longevity Jobs

4. A Tour of All Mitochondria Longevity Companies

5. Tweet of the Week

Dear Longevity Nerds: 🎉🎉🎉We have reached 925 subscribers -- still doubling every ~7 weeks. The movement is growing stronger and stronger every day thanks to early adopters like you! Spread the word about longevity biotechnology and we can solve aging even faster.

Note: Sorry this week’s newsletter is a bit long (14,000+ words, R.I.P. your inbox). Future newsletters will be much shorter now that this particular topic is out of the way. 

Edit: I broke Substack — I am forced to split the newsletter into Part 1 and Part 2.

-NATHAN

Disclaimer: None of this should be taken as financial advice. This information is for educational purposes only. 

📝Last Week in Longevity

• BioAge enters the clinic with Phase 2a trial. Kristen Fortney’s a16z-backed AI/ML drug discovery startup announced it had initiated a Phase 2a clinical trial of BGE-117 to treat unexplained adult anemia (UAA), an age-related disease that affects 10% of those over 65 years of age. Topline data is expected in H1 2022. 

  BGE-117 is a Hypoxia-Inducible Factor (HIF) activator licensed from Taisho Pharmaceuticals that has been shown to increase Hb and EPO levels in humans without UAA in Phase 1 trials. BGE-117 may also have benefits that extend to broader aging: BioAge mined proprietary biobanks to determine that individuals that had higher levels of HIF were much more likely to live past 85. A success here would not only be huge for the longevity industry but also AI/ML drug discovery as a whole. Truly exciting.

• Christian Angermayer’s Apeiron SPAC -- David Sinclair and Peter Attia to be co-chairmen. Angermayer’s Frontier Acquisition Corp, a blank-check SPAC company, will list as early as March. Angermayer is also a founder and financier of Cambrian Biopharma, a multi-portfolio longevity biotech company that came out of stealth this month. Peter Attia, a medical doctor with a longevity practice and popular podcast, is well known in the longevity/biohacking space (as is David Sinclair). I’m guessing this is a nutraceuticals or wellness play and not a deep biotech acquisition.

• ChromaDex (NYSE:CDXC) stock surges over 100% on Phase 3 COVID recovery trials. ChromaDex is the maker of TruNiagen, a nicotinamide riboside (NR) NAD+ boosting supplement. In a preprint posted on medrXiv,